Clinical Trial Update: ENERGI-F703 for Diabetic Foot Ulcers Phase II Study [Phase 2]

View source ↗

Summary

Phase II trial update for ENERGI-F703 in diabetic foot ulcers has completed enrollment/status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Diabetic Foot Ulcer
• Foot Disease
• Wound Healing Impairment

Drugs mentioned

• ENERGI-F703

Snippet

Sponsor: Energenesis Biomedical Co., Ltd. | Conditions: Diabetic Foot, Foot Ulcer | Phase 2 | Status: COMPLETED